The EC approved Libtayo – a fully human monoclonal antibody ... therapeutics for the treatment of cancer. Meanwhile, another company focused on advanced cervical cancer is Nykode Therapeutics ...

Biotech company Regeneron (NASDAQ:REGN) missed Wall Street’s revenue expectations in Q1 CY2025, with sales falling 3.7% year ...

Based in Tarrytown, New York, the company’s products include EYLEA, Dupixent, Libtayo, Praluent, REGEN-COV, and Kevzara. The company is expected to report its Q1 earnings on Tuesday, Apr. 29 ...

TARRYTOWN, N.Y., May 01, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: REGN) today announced new and updated data from its oncology and hematology portfolio will be shared at the ...

If approved, Libtayo will take on some heavyweight competition ... s Opdivo (nivolumab), which has been combined with the company’s CTLA4 inhibitor Yervoy (ipilimumab) in an arm of the CheckMate ...

Progression-free survival data from more than 30 patients with first line pancreatic cancer in the ongoing Phase 2a trial of IMM-1-104 trial planned for announcement in 2Q’25 - - Reported positive ...